Sunday, June 15th, 2025

ComfortDelGro Expands UK Presence with Addison Lee Acquisition: Analyst Raises Fair Value

Deep Dive into ComfortDelGro Corporation: An Equity Research Analysis

Date of Report: 15 November 2024
Broker: OCBC Investment Research Private Limited

Introduction

In this comprehensive equity research report, we explore the financial health and future projections of ComfortDelGro Corporation, a leading player in the global transportation industry. The analysis is geared for investors seeking to understand the intricacies of this Singapore-based company’s operations, financial performance, and strategic direction.

ComfortDelGro Corporation: Acquisition-Fueled Growth

ComfortDelGro Corporation (CD) is a major global transportation company operating across diverse segments, including public transport, taxi, private hire vehicles, and more. This report highlights CD’s impressive performance in the first nine months of 2024, which slightly exceeded expectations. Revenue and operating profit rose by 15.4% and 19% year-on-year, respectively.

Strategic Acquisitions as Growth Catalysts

The acquisition of Addison Lee, a private UK ground transport company, marks a significant milestone for CD. This strategic move is expected to bolster the company’s taxi and private hire business, expanding its customer base. The acquisition was completed on 7 November 2024, adding 7,500 drivers and 5,000 vehicles to CD’s fleet.

Financial Performance and Projections

CD’s 9M24 results were promising, with 3Q24 revenue and operating profit showing significant quarter-on-quarter growth. Revenue increased by 6.1% to SGD1.2 billion, while operating profit grew by 6.6% to SGD90.1 million. The public transport segment outperformed expectations, contributing significantly to this growth.

ESG and Governance

ComfortDelGro has shown improvement in its ESG scores over the years, especially in governance. However, there is room for improvement in labor management, carbon emissions, and health and safety. The company’s strong governance structures are supported by robust policies such as ethics audits and whistleblower protection.

Investment Thesis and Risks

The investment thesis for CD is rooted in its ability to defend and grow its core business while expanding into new areas like electric vehicles and autonomous fleets. Potential catalysts for growth include breakeven on Singapore’s Downtown line and recovery in transport activity levels. However, risks such as inflation, supply chain issues, and competition from ride-hailing services like Grab and Gojek remain.

Financial Summary and Valuation

The financial summary for FY23 to FY25E projects consistent growth in revenue and operating profit. The company maintains a stable operating profit margin, with key financial ratios reflecting steady improvement. The fair value estimate for CD has been revised to SGD1.67, reflecting the accretive nature of recent acquisitions.

Conclusion

ComfortDelGro Corporation stands out as a robust investment opportunity in the transportation sector. With strategic acquisitions and a strong focus on ESG, the company is poised for sustainable growth. The BUY recommendation from OCBC Investment Research is a testament to CD’s potential for delivering solid returns to investors.

This detailed analysis provides a comprehensive view of ComfortDelGro’s current standing and future prospects, making it a valuable read for investors interested in the transportation industry.

Plover Bay Technologies: Strong Growth Momentum and Rising Opportunities in 2024

Date of Report: 24 September 2024Broker Name: UOB Kay Hian Company Overview Plover Bay Technologies (1523 HK) is a small-mid cap company that has shown remarkable growth in 2024, continuing its solid momentum from...

Hang Lung Properties: Positioned for Growth in China’s Real Estate Landscape Amid Economic Recovery

Date of Report October 1, 2024 Broker Name CGS International Securities Company Overview Hang Lung Properties is a leading real estate company in China, focusing on property development and investment, particularly in the retail...

China Shineway Pharmaceutical Group Limited – 2024 Results Disappoint, Targets 10% Revenue Growth in 2025

China Shineway Pharmaceutical Faces Challenges, Eyes 10% Revenue Growth in 2025 UOB Kay Hian | March 31, 2025 China Shineway Pharmaceutical Group Limited (2877 HK) reported its 2024 results, which missed expectations, with revenue...